🇺🇸 FDA
Pipeline program

EVEROLIMUS

CRAD001M2X02B

Phase 3 small_molecule active

Quick answer

EVEROLIMUS for Refractory seizures associated with tuberous sclerosis complex is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Refractory seizures associated with tuberous sclerosis complex
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials